Sauna-induced acceleration in insulin absorption from subcutaneous injection site
British Medical Journal
|June 14, 1980
Summary
Finnish sauna use significantly speeds up insulin absorption in diabetic patients, leading to lower blood glucose levels. This enhanced insulin uptake may necessitate dietary adjustments or reduced insulin dosage to prevent hypoglycemia.
Area of Science:
- Endocrinology
- Metabolic Health
Background:
- Insulin therapy is crucial for managing insulin-dependent diabetes.
- Understanding factors influencing subcutaneous insulin absorption is vital for glycemic control.
Purpose of the Study:
- To investigate the impact of Finnish sauna exposure on insulin absorption rates.
- To determine the effect of accelerated insulin absorption on blood glucose levels in diabetic patients.
Main Methods:
- Eight insulin-dependent diabetic patients participated in the study.
- Externally measured the disappearance rate of 125I-labelled rapid-acting insulin.
- Sauna sessions involved two 25-minute exposures at 85°C, compared to room temperature controls.
Main Results:
- Sauna exposure accelerated insulin absorption by 110% (p < 0.01).
- Post-sauna blood glucose levels decreased by 3.0-3.3 mmol/l (p < 0.05).
- The reduction in blood glucose was proportional to the increased insulin absorption rate (r = 0.30, p < 0.01).
Conclusions:
- Finnish sauna use enhances insulin absorption from subcutaneous injection sites in diabetic individuals.
- The observed hypoglycemic effect is partly attributed to this accelerated insulin uptake.
- Preventive measures like snacks or reduced insulin doses may mitigate sauna-induced hypoglycemia.
More Related Videos
08:01Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
Published on: May 16, 2021
06:13Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
Related Concept Videos
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:25Routes of Drug Administration: Parenteral
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...